XYWAV Drug Patent Profile

Which patents cover Xywav, and when can generic versions of Xywav launch?

Xywav is a drug marketed by Jazz and is included in one NDA. There are sixteen patents protecting this drug and one Paragraph IV challenge.

The generic ingredient in XYWAV is calcium oxybate; magnesium oxybate; potassium oxybate; sodium oxybate. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the calcium oxybate; magnesium oxybate; potassium oxybate; sodium oxybate profile page.

DrugPatentWatch^® Generic Entry Outlook for Xywav

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be August 12, 2028. This may change due to patent challenges or generic licensing.

There have been twenty-three patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for XYWAV

US Patents:	16
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Drug Prices:	Drug price information for XYWAV
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for XYWAV
What excipients (inactive ingredients) are in XYWAV?	XYWAV excipients list
DailyMed Link:	XYWAV at DailyMed

See drug prices for XYWAV

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for XYWAV

Constraining patent/regulatory exclusivity:

THE TREATMENT OF IDIOPATHIC HYPERSOMNIA (IH) IN ADULTS

NDA:

212690

Dosage:

SOLUTION;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for XYWAV

Drug Class	Central Nervous System Depressant
Physiological Effect	Central Nervous System Depression Decreased Central Nervous System Organized Electrical Activity

Paragraph IV (Patent) Challenges for XYWAV

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
XYWAV	Oral Solution	calcium oxybate; magnesium oxybate; potassium oxybate; sodium oxybate	0.234 g/0.096 g/ 013 g/0.04 g per mL	212690	1	2021-04-12

US Patents and Regulatory Information for XYWAV

XYWAV is protected by seventeen US patents and three FDA Regulatory Exclusivities.

This potential generic entry date is based on THE TREATMENT OF IDIOPATHIC HYPERSOMNIA (IH) IN ADULTS.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Jazz	XYWAV	calcium oxybate; magnesium oxybate; potassium oxybate; sodium oxybate	SOLUTION;ORAL	212690-001	Jul 21, 2020		RX	Yes	Yes
Jazz	XYWAV	calcium oxybate; magnesium oxybate; potassium oxybate; sodium oxybate	SOLUTION;ORAL	212690-001	Jul 21, 2020		RX	Yes	Yes
Jazz	XYWAV	calcium oxybate; magnesium oxybate; potassium oxybate; sodium oxybate	SOLUTION;ORAL	212690-001	Jul 21, 2020		RX	Yes	Yes			Y
Jazz	XYWAV	calcium oxybate; magnesium oxybate; potassium oxybate; sodium oxybate	SOLUTION;ORAL	212690-001	Jul 21, 2020		RX	Yes	Yes
Jazz	XYWAV	calcium oxybate; magnesium oxybate; potassium oxybate; sodium oxybate	SOLUTION;ORAL	212690-001	Jul 21, 2020		RX	Yes	Yes					Y
Jazz	XYWAV	calcium oxybate; magnesium oxybate; potassium oxybate; sodium oxybate	SOLUTION;ORAL	212690-001	Jul 21, 2020		RX	Yes	Yes
Jazz	XYWAV	calcium oxybate; magnesium oxybate; potassium oxybate; sodium oxybate	SOLUTION;ORAL	212690-001	Jul 21, 2020		RX	Yes	Yes			Y

International Patents for XYWAV

See the table below for patents covering XYWAV around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2013359114
Brazil	112015014007	composições de gama-hidroxibutirato e sua utilização para o tratamento de distúrbios
Canada	2894876	COMPOSITIONS DE GAMMA-HYDROXYBUTYRATE ET LEUR UTILISATION POUR LE TRAITEMENT DE TROUBLES (GAMMA-HYDROXYBUTYRATE COMPOSITIONS AND THEIR USE FOR THE TREATMENT OF DISORDERS)
China	105025892	γ‑羟基丁酸盐组合物及其治疗疾病的用途 (Gamma-hydroxybutyrate compositions and their use for the treatment of disorders)
Cyprus	1119918
Cyprus	1123498
Denmark	2931268

Supplementary Protection Certificates for XYWAV

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0247633	62/1997	Austria		PRODUCT NAME: ATORVASTATIN CALCIUM; NAT. REGISTRATION NO/DATE: 1-21926, 1-21927, 1-21928 19970411; FIRST REGISTRATION: GB PL 00018/0240 - PL 00018/0242 19961107
0720599	CR 2014 00050	Denmark		PRODUCT NAME: EZETIMIBE AND ATORVASTATIN OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, INCLUDING ATORVASTATIN AS ATORVASTATIN CALCIUM TRIHYDRATE; REG. NO/DATE: DE/H/3895-3898/001-004/DC 20140910
0933372	PA2008006	Lithuania		PRODUCT NAME: FOSAMPRENAVIR CALCIUM; REGISTRATION NO/DATE: EU/1/04/282/001-002 20040712
0933372	PA2008006,C0933372	Lithuania		PRODUCT NAME: FOSAMPRENAVIR CALCIUM; REGISTRATION NO/DATE: EU/1/04/282/001-002 20040712
0933372	SPC/GB08/018	United Kingdom		PRODUCT NAME: FOSAMPRENAVIR CALCIUM: ((1S,2R)-3-(((4-AMINOPHENYL)SULFONYL)(2-METHYLPROPYL)AMINO)-1-(PHENYLMETHYL)-2(PHOSPHONOOXY)PROPYL)-CARBABAMIC ACID C-((3S)-TETRAHYDRO-3-FURANYL) ESTER CALCIUM SALT; REGISTERED: UK EU/1/04/282/001 20040712; UK EU/1/04/282/002 20040712
0521471	SPC/GB03/033	United Kingdom		PRODUCT NAME: ROSUVASTATIN OPTIONALLY IN THE FORM OF A NON-TOXIC PHARMACEUTICALLY ACCEPTABLE SALT, PARTICULARLY THE CALCIUM SALT.; REGISTERED: NL 26872 20021106; NL 26873 20021106; NL 26874 20021106; UK PL 17901/0201 20030321; UK PL 17901/0202 20030321; UK PL 17901/0203 20030321
0521471	C300125	Netherlands		PRODUCT NAME: ROSUVASTATINUM, DESGEWENST IN DE VORM VAN EEN NIET-TOXISCH FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER HET CALCIUMZOUT; REGISTRATION NO/DATE: RVG 26872 - RVG 26874 20021106

Last updated: July 27, 2026

XYWAV market dynamics and financial trajectory (2026 update)

XYWAV (oxybate salts; GHB-related narcolepsy and cataplexy medicine) is an established, higher-cost CNS/sleep franchise driven by (1) narcolepsy with cataplexy conversion, (2) payer mix and rebate intensity, and (3) dosing-product/channel expansion constraints tied to product access, REMS-like distribution controls (where applicable), and controlled-substance logistics. Financial trajectory has been shaped by competitive intensity in narcolepsy symptom management, insurance coverage pressure, and ongoing shift toward specialty pharmacy fulfillment. Public financials are not available in the provided input set to quantify exact revenue, unit trends, gross-to-net, or segment attribution across years; the analysis below focuses on market structure, price/rebate mechanics, and competitive dynamics that govern XYWAV’s revenue performance.

---

What is the XYWAV market landscape and who competes with it in narcolepsy?

XYWAV is used for narcolepsy-related excessive daytime sleepiness and cataplexy. Its market dynamics sit inside the broader narcolepsy symptom market, where competitors target wakefulness, cataplexy control, or both, but differ in mechanism, dosing burden, and payer preferences.

Core competitive pressure by treatment target

• Wake promotion / EDS management: stimulants and wake-promoting agents compete for payer dollars allocated to EDS.
• Cataplexy control: sodium oxybate products (including other oxybate formulations where available) are the closest symptom-aligned substitutes.
• Symptom-channel effects: even when competitors do not fully replace oxybates, they can reduce oxybate initiation in patients with partial response history or where coverage criteria favor cheaper alternatives.

How payers typically structure coverage

• Step edits and prior authorization: common for high-cost CNS drugs; payers often require documented diagnosis and treatment history.
• Specialty pharmacy requirement: controlled substance handling increases logistics-based formulary steering.
• Rebate intensity tied to network access: reimbursement trajectory in specialty CNS is highly dependent on formulary placement, net price, and adherence rates.

---

How do payer dynamics and gross-to-net pressure affect XYWAV revenue performance?

XYWAV’s financial trajectory is sensitive to gross-to-net because oxybate-class medicines tend to face:

• rebate renegotiations as formularies turn over,
• utilization controls tied to REMS-like distribution requirements and pharmacy constraints,
• and competition that drives net price compression even if gross list price is stable.

Gross-to-net mechanics that drive the income statement

• Rebates and chargebacks: payers and PBMs use formulary placement to demand higher rebates, increasing deductions from gross sales.
• Commercial mix and Medicare/managed care: the proportion of patients in commercial vs. Medicare Advantage materially changes rebate magnitude.
• Channel growth does not always translate to net growth: specialty pharmacy distribution can increase units while net revenue lags if rebates rise faster than list price.

What “market access” typically looks like in practice

• Broad access in high-rebate networks supports volume, but often at the cost of margin.
• Narrow access strategies protect net pricing but cap TAM conversion and delay new patient uptake.

---

When does XYWAV face exclusivity and patent expiration timelines risk?

Exclusivity and patent-driven risk in oxybate salts depends on the specific patent estate covering:

• active ingredient (oxybate salts),
• formulation (salt form and composition),
• method of use (narcolepsy indications, dosing regimens),
• and manufacturing/process protections.

Public, exact expiry dates and Orange Book-controlled expiration windows are not included in the provided input set. Without those listings and specific patent numbers, a defensible timeline cannot be constructed.

---

What patent estate protects XYWAV and how strong is it against generic entry?

Generic entry risk for oxybate-class drugs is usually constrained by:

• formulation and manufacturing method patents,
• method-of-use claims tied to specific narcolepsy endpoints and dosing schedules,
• and regulatory barriers around controlled-substance distribution.

A complete strength assessment requires Orange Book patent identifiers, claim scopes, and any litigation record. Those are not present in the provided input set; therefore, the patent-strength scoring cannot be reliably quantified.

---

What formulations are protected for XYWAV and could reformulation launch substitutes emerge?

Formulation and process patents can support long-lived market differentiation even when active-ingredient protection weakens. For oxybate salts, formulation risk often hinges on:

• salt ratios and composition,
• particle/crystal properties that affect stability and bioavailability,
• dosing performance with controlled-substance handling,
• and manufacturing process controls that support consistency.

Without the specific formulation patent listings tied to XYWAV, substitution pathways cannot be mapped to legal barriers.

---

How do Paragraph IV filings or biosimilar-style challenges compare for XYWAV?

XYWAV is a small-molecule drug, so it is not directly subject to biosimilar frameworks. The closest analog is generic small-molecule challenge through ANDA mechanisms, including:

• Paragraph IV certifications referencing listed patents,
• potential settlements that delay launch,
• and litigation outcomes that determine timing.

The provided input set does not include any ANDA/Paragraph IV docket identifiers, court outcomes, or settlement terms, so the timing and risk profile cannot be stated as fact.

---

What is the FDA and Orange Book status of XYWAV (exclusivity and listed patents)?

A defensible Orange Book status requires:

• drug product NDC(s),
• listed patents and their expiration dates,
• exclusivity codes,
• and any changes in labeling tied to approval history.

No FDA Orange Book extract or patent listing table is provided in the input set, so status cannot be reported accurately.

---

How does XYWAV compare with other oxybate options for narcolepsy patients and prescribers?

Prescriber choice within the oxybate class depends on:

• dosing schedule convenience,
• tolerability and adherence,
• payer coverage and step edits,
• and practical pharmacy fulfillment capability for controlled-substance distribution.

Substitution dynamics

• Close substitute: oxybate alternatives (when covered) compete most directly because they target the same symptoms.
• Less direct substitute: wake-promoting agents compete for EDS but may not replace night-time symptom control, leaving oxybates for partial responders or those who fail first-line wake agents.

Net effect on financial trajectory

• If competing oxybate options gain formulary share or net access, XYWAV’s unit growth slows and margin compresses.
• If XYWAV maintains preferred access, the trajectory remains dominated by adherence and new patient conversion.

---

What generic entry risks exist for XYWAV and what would generic launch scenarios look like?

Generic entry risk is typically driven by:

• availability of an eligible ANDA pathway,
• ability to demonstrate bioequivalence with the required controlled-substance distribution,
• and patent/litigation clearance.

Because specific listed patents and litigation events are not provided, generic scenario probability cannot be quantified. A complete scenario table also requires known patent expiry dates and whether any carve-outs exist for specific strengths or dosage forms.

---

Which companies are challenging XYWAV and what litigation impacts matter?

A litigation impact assessment requires:

• ANDA filer identities,
• Paragraph IV notice dates,
• case numbers,
• court rulings,
• and any settlement “trigger” dates.

No litigation data is included in the provided input set, so the identity of challengers and the effect on launch timing cannot be stated.

---

How do specialty pharmacy logistics and controlled-substance distribution affect XYWAV commercial velocity?

Controlled-substance medicines face structural distribution constraints that can shape adoption curves:

• fewer dispensing sites,
• higher reliance on specialty pharmacy networks,
• tighter forecasting and fulfillment processes,
• and additional patient onboarding steps.

Commercially, this affects:

• time-to-fill after prior authorization approval,
• adherence rates (refill friction changes continuation),
• and payer switching costs (network lock-in can sustain share even under list price pressure).

---

Revenue trajectory drivers: what specific factors determine XYWAV growth or decline?

Without exact year-by-year financials, the most actionable view is to map drivers that determine whether growth is volume-led or price/net-led.

Volume-led growth levers

• diagnosis growth in narcolepsy with cataplexy,
• improved payer access for new initiations,
• improved adherence and persistence after onboarding.

Net revenue pressure levers

• gross-to-net increases due to payer/PBM rebate intensification,
• increased utilization of cheaper substitutes for EDS,
• turnover of PBM contracts that shift formulary tiers.

Margin structure levers

• specialty distribution scale and channel mix,
• supply chain stability for controlled-substance inventory,
• mix between strengths/dosing regimens affecting cost of goods.

---

Commercial exposure: how much revenue is at risk from competitive substitution?

Competitive substitution risk is highest where:

• payers prefer cheaper EDS agents first,
• oxybate alternatives capture access through network contracting,
• or patient populations are partly non-refractory to wake-promoting regimens.

Quantification requires XYWAV revenue by segment and competitor-specific access changes, which are not present in the provided input set.

---

Key takeaways

• XYWAV’s market dynamics are governed by specialty payer access, rebate intensity, and controlled-substance distribution constraints that shape conversion and persistence.
• The financial trajectory is likely to track gross-to-net pressure and substitution in narcolepsy symptom management, especially within EDS-heavy and partially controlled patient subsets.
• A defensible exclusivity, patent, and launch-risk timeline cannot be produced from the provided input set because Orange Book listings, patent numbers, expiry dates, and litigation records are not included.
• The most decision-relevant levers for forecasting are formulary placement changes, rebate renegotiation cycles, and pharmacy-network onboarding friction.

---

FAQs

1) What payer utilization controls typically apply to XYWAV?
Common controls include prior authorization, step edits after documented treatment history, and specialty pharmacy fulfillment.

2) Does XYWAV face substitution from wake-promoting agents in narcolepsy?
Yes. EDS management competitors can reduce oxybate starts in patients where EDS control is achieved without night-time symptom dependence.

3) Are oxybate formulation and dosing regimen patents the main barriers to generic entry for drugs like XYWAV?
For oxybate-class products, formulation/process and method-of-use protections are often central barriers, though exact scope depends on listed XYWAV patents.

4) How does specialty pharmacy channel mix affect XYWAV net revenue?
Channel mix affects net revenue through rebate and chargeback magnitude and through refill/persistence outcomes that influence unit persistence.

5) What indicators best predict XYWAV revenue trajectory in the near term?
Formulary changes (tier placement), contract renewals with PBMs, and evidence of persistence/adherence in specialty pharmacy data.

---

References (APA)

1. No sources were provided in the input set.

DrugChatter Q&A for XYWAV

Xywav sales?
Xywav generic name?